HC Wainwright Has Negative View of Annovis Bio Q4 Earnings

Annovis Bio, Inc. (NYSE:ANVS) – Equities research analysts at HC Wainwright dropped their Q4 2024 EPS estimates for shares of Annovis Bio in a report issued on Monday, November 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.38) for the quarter, down from their prior forecast of ($0.30). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Annovis Bio’s current full-year earnings is ($1.99) per share. HC Wainwright also issued estimates for Annovis Bio’s Q1 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.76) EPS and FY2025 earnings at ($2.32) EPS.

A number of other analysts have also recently issued reports on ANVS. EF Hutton Acquisition Co. I upgraded shares of Annovis Bio to a “strong-buy” rating in a research note on Tuesday, August 13th. Maxim Group upgraded shares of Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Friday, October 25th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $32.17.

Annovis Bio Price Performance

Shares of Annovis Bio stock opened at $6.94 on Thursday. Annovis Bio has a 1 year low of $4.53 and a 1 year high of $22.49. The company has a market capitalization of $95.77 million, a price-to-earnings ratio of -1.66 and a beta of 1.70. The business has a fifty day simple moving average of $8.47 and a two-hundred day simple moving average of $8.27.

Annovis Bio (NYSE:ANVS) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.33).

Institutional Investors Weigh In On Annovis Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in Annovis Bio by 6.1% during the first quarter. Vanguard Group Inc. now owns 357,942 shares of the company’s stock worth $4,260,000 after purchasing an additional 20,588 shares during the period. Quest Partners LLC acquired a new position in shares of Annovis Bio in the 3rd quarter valued at approximately $371,000. XTX Topco Ltd bought a new stake in shares of Annovis Bio during the 2nd quarter worth approximately $115,000. Greenwich Wealth Management LLC lifted its holdings in shares of Annovis Bio by 9.3% during the 3rd quarter. Greenwich Wealth Management LLC now owns 16,475 shares of the company’s stock worth $133,000 after acquiring an additional 1,400 shares during the period. Finally, Cetera Advisors LLC acquired a new stake in shares of Annovis Bio during the 1st quarter worth approximately $122,000. 15.83% of the stock is currently owned by institutional investors and hedge funds.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.